Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

AustriaBack to Austria

Clinical trials in Linz – page 26

419 clinical trials in Linz, Austria across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Linz at a glance
419
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

419 trials in Linz

Open in trial search

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GWT-Tud GmbH

Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

Not recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Genmab A/S

Chronic graft versus host disease

Not recruiting

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Acute myeloid leukaemia

Not recruiting

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Prostate cancer recurrent

Not recruiting

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Squamous cell carcinoma of head and neck

Not recruiting

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab with Platinum-Based Chemotherapy for Patients with Early-Stage Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Not recruiting

Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

HER2 positive breast cancer

Not recruiting

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Linz

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on various forms of cancer, including prostate cancer, colorectal cancer, and lung cancer. Studies are evaluating novel therapeutic approaches and combination treatments.

  • Metastatic cancer treatments
  • Immunotherapy combinations
  • Novel drug therapies

Particular emphasis on personalized treatment approaches and targeted therapies for specific cancer types.

02 Autoimmune Conditions

Research targeting inflammatory and autoimmune disorders, including Crohn's Disease, plaque psoriasis, and uveitis. Studies evaluate new biological treatments and combination therapies.

  • Inflammatory disease management
  • Novel biological agents
  • Treatment resistance solutions

Focus on improving disease control and patient outcomes through innovative therapeutic approaches.

03 Cardiovascular and Metabolic Studies

Trials investigating treatments for cardiovascular disease and obesity, with emphasis on preventive measures and innovative therapeutic solutions.

  • Cardiovascular risk reduction
  • Metabolic disorder management
  • Safety assessments

Research aimed at developing safer and more effective treatments for metabolic and cardiovascular conditions.

Back to AustriaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.